476060.KQ Onconic Therapeutics Inc.

Healthcare Drug Manufacturers - Specialty & Generic KOSDAQ
12,110 KRW
Close of Oct 30, 2026
8,790 28,900
Market cap
KRW 550B
P/E
23.6x
P/B
6.41x
ROE
23.8%
Dividend yield
-
Fundamental score
1.6/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 476060.KQ undervalued?

Graham number
Price12,110
Graham value4,667
Premium159.5%

476060.KQ trades 159.5% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Onconic Therapeutics Inc. fundamental analysis

7 of 22 checks passed

ROE 2/2

High return on equity (23.8%), above 20%.

ROA 1/1

Return on assets (21.9%) is above the industry median (5.4%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share history is shorter than 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (147.4%) is above the industry median (88.7%).

Revenue Growth 2/2

Revenue grew 725.2% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 0/1

Debt is not reported.

Interest Coverage 1/1

EBIT is 2,345.8x against interest expense, well covered.

PE vs Market 0/1

PE (23.6x) is above the market median (11.3x).

PE vs Industry 0/1

PE (23.6x) is above the industry median (19.0x).

PBV 0/1

Price to book (6.4x) is above the industry median (1.5x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 151.5, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Onconic Therapeutics Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Onconic Therapeutics Inc.

Onconic Therapeutics Inc. engages in the research and development of anti-cancer therapy in South Korea. It develops Zastaprazan (OCN-101), a potassium-competitive acid blocker, which is in phase 3 for the treatment of gastric acid related disease; and OCN-201 (JPI-547), an anticancer drug; JP-1366, a treatment for peptic ulcer; and drugs for DDR and immuno-oncology fields. JP-1366, a poly ADP-ribose polymerase inhibitor, which is in phase 1 for the treatment of pancreatic c…

Full company profile